This meeting took place in the past. For a complete list of the meetings for the upcoming/current season, see our meeting list or click on related meetings tab below to check for related meeting(s).
Web Desc
Molecular and Cellular Biology of Immune Escape in Cancer
joint with Role of Inflammation in Oncogenesis
Organizer(s): George C. Prendergast and Dmitry I. Gabrilovich
Date: February 07 - 12, 2010
Location: Keystone Resort, Keystone, CO, USA
Sponsored by Astellas Pharma Inc. and Genentech BioOncology
Summary of Meeting:
It is now widely recognized that the immune microenvironment of a tumor provides critical support in determining its progression versus dormancy or destruction. To gain immune benefits the tumor must evolve mechanisms of immune escape. Study of this crucial process requires cross-fertilization between molecular cell biologists and tumor immunologists who do not tend to interact. This problem is also integrated with the problem of cancer inflammation that has captured the attention of tumor biologists focused on transgenic mouse models and clinical settings. Thus, we propose a unique conference – the first of its kind – to integrate perspectives from a diverse set of researchers in cancer, immunology, and molecular therapeutics and to focus specifically on immune escape and tumor-induced immune suppression as a multidisciplinary problem. Cancer is initiated by the accumulation of genetic and epigenetic changes in a normal cell, but its progression depends on the stromal and immune microenvironment of the initiated cell. While intrinsic signals within the initiated cell drive neoplastic transformation and genomic plasticity, extrinsic signals delivered by immune cells are critical in dictating whether progression versus dormancy or destruction of an initiated lesion takes place, and also whether metastasis may occur. The high degree of genomic plasticity in cancer cells permits them to develop sophisticated ways to prevent the immune system from recognizing and eliminating tumor cells. It has become increasingly clear in recent years that abnormalities in the immune system that are induced by tumors not only hamper natural anti-tumor immune surveillance but also limit the efficacy of immunotherapy and even traditional chemotherapy and radiotherapy. Thus, tumor-induced immune abnormalities may not only impact the clinical course of disease but also the prospects for its therapeutic management. Recent results indicate that we are on the verge of a real breakthrough in our understanding of how tumors thwart the immune system and how correcting immune escape could vastly improve cancer therapy. However, at present the available mechanistic information presents a somewhat convoluted picture that includes some seemingly contradictory elements. While this situation is a natural stage of development in the field, there is nevertheless a pressing need to define key questions and organize their development in coherent ways that can speed improvements in cancer therapy.
Scholarship Deadline: October 7 2009
Discounted Abstract Deadline: October 7 2009
Abstract Deadline: November 6 2009
Discounted Registration Deadline: December 7 2009
We gratefully acknowledge additional support for this conference from:
Astellas Pharma Inc.CytoAnalyticsGenentech BioOncologyRoyal Society of Chemistry


George Prendergast
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1R13CA144231-01
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found